Galapagos NV logo

Galapagos NVNASDAQ: GLPG

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Belgium

IPO:

27 February 2012

Next earnings report:

23 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.83 B
-61%vs. 3y high
79%vs. sector
-98%vs. 3y high
12%vs. sector
-64%vs. 3y high
31%vs. sector
-94%vs. 3y high
66%vs. sector

Price

regular market | 7 min ago
$27.80+$0.23(+0.85%)

Dividend

No data over the past 3 years
$65.82 M$74.25 M
$65.82 M-$55.46 M

Analysts recommendations

Institutional Ownership

GLPG Latest News

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
globenewswire.com07 October 2024 Sentiment: POSITIVE

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024.

Galapagos receives transparency notification from EcoR1 Capital
globenewswire.com16 September 2024 Sentiment: NEUTRAL

Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
zacks.com23 August 2024 Sentiment: POSITIVE

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

Galapagos receives transparency notification from FMR LLC
globenewswire.com20 August 2024 Sentiment: NEUTRAL

Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.

Galapagos reports half-year 2024 financial results and provides second quarter business update
globenewswire.com01 August 2024 Sentiment: NEUTRAL

Webcast presentation   with management on   2   August 2024,   at 14:00 CET   /   8:00 AM ET,   www.glpg.com

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
newsfilecorp.com30 May 2024 Sentiment: POSITIVE

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications Adaptimmune will hold a conference call tomorrow (May 31 st ) at 8 a.m. EDT (webcast link here and more details below) Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 30, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), and Galapagos NV (NA: GLPG) (NASDAQ: GLPG) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.

Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript
Seeking Alpha04 May 2024 Sentiment: NEUTRAL

Galapagos NV (NASDAQ: GLPG) held its Q1 2024 Results Conference Call on May 3, 2024 at 8:00 AM ET. The call featured company representatives including Sofie Van Gijsel, Paul Stoffels, Thad Huston, and Jeevan Shetty. Various analysts and investors also participated in the call. Sofie Van Gijsel welcomed everyone to the audio webcast of Galapagos' Q1 2024 Results on behalf of the reporting team.

After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
Zacks Investment Research03 April 2024 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
Zacks Investment Research18 March 2024 Sentiment: POSITIVE

Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript
Seeking Alpha05 November 2023 Sentiment: NEUTRAL

Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of Clinical Development, Oncology Conference Call Participants Xian Deng - UBS Dane Leone - Raymond James Johoon Kim - RBC Capital Markets Jason Gerberry - Bank of America Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call.

What type of business is Galapagos NV?

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

What sector is Galapagos NV in?

Galapagos NV is in the Healthcare sector

What industry is Galapagos NV in?

Galapagos NV is in the Biotechnology industry

What country is Galapagos NV from?

Galapagos NV is headquartered in Belgium

When did Galapagos NV go public?

Galapagos NV initial public offering (IPO) was on 27 February 2012

What is Galapagos NV website?

https://www.glpg.com

Is Galapagos NV in the S&P 500?

No, Galapagos NV is not included in the S&P 500 index

Is Galapagos NV in the NASDAQ 100?

No, Galapagos NV is not included in the NASDAQ 100 index

Is Galapagos NV in the Dow Jones?

No, Galapagos NV is not included in the Dow Jones index

When was Galapagos NV the previous earnings report?

No data

When does Galapagos NV earnings report?

The next expected earnings date for Galapagos NV is 23 February 2025